Skip to main content
. Author manuscript; available in PMC: 2010 Oct 1.
Published in final edited form as: JAMA. 2010 Sep 1;304(9):967–975. doi: 10.1001/jama.2010.1237

Table 3.

Risk-Reducing Oophorectomy (RRSO) and Breast Cancer (BC) Risk*

No Prior Breast Cancer ** Prior Breast Cancer ***
Total BRCA1 BRCA2 Total BRCA1 BRCA2
Total Participants 1,370 869 501 647 397 250
RRSO (“Exposed”) 336 236 100 208 138 70
N (%) Post-RRSO BC 39 32 (14%) 7 (7%) 23 19 (14%) 4 (6%)
No RRSO (“Controls”) 1,034 633 401 439 259 180
N (%) Controls with BC 223 129 (20%) 94 (23%) 60 46 (18%) 14 (8%)
Mean Age at RRSO (Yrs) 43.8 (20.5-
79.0)
42.7 (20.5-
79.0)
46.6 (35.4-
68.5)
48.5 (29.8-
74.8)
48.2 (29.8-
74.8)
49.1 (34.0-
69.5)
Mean Start Age (Yrs, for Controls) 36.2 (18.1-
90.4)
35.0 (18.2-
90.4)
38.1 (18.1-
82.7)
44.8 (21.9-
86.2)
43.3 (21.9-
86.2)
47.1 (27.1-
77.7)
Mean Follow-up to BC (Yrs) 4.7 (0.5-21.0) 4.7 (0.5-21.0) 4.8 (0.5-20.6) 4.4 (0.5-16.1) 4.5 (0.5-16.1) 4.0 (0.7-11.7)
Mean Follow-up to Censoring
(Yrs)
4.7 (0.5-27.8) 4.7 (0.5-27.7) 4.7 (0.5-27.8) 3.8 (0.5-18.4) 3.7 (0.5-18.4) 3.9 (0.5-15.4)
HR**** (95% CI) 0.54 (0.37-
0.79)
0.63 (0.41-
0.96)
0.36 (0.16-
0.82)
1.00 (0.56-
1.77)
1.01 (0.54-
1.89)
1.11 (0.31-
3.98)
*

Participants censored at OC, RRM, death, or last contact.

**

No breast cancer prior to RRSO, or in the controls prior to the start of follow up.

***

Breast cancer allowed prior to RRSO or start of follow up

****

Adjusted for year of birth and stratified by center.

HHS Vulnerability Disclosure